Werkgroep Cardiologische centra Nederland

AEGIS (Cancelled)

A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
Medicine
CSL112
Population
ASCVD
Phase
IIb
Starting year
2014

Publications: AEGIS

  • Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)Circulation - Oude Ophuis, dr. A.J.M. - AEGIS - ASCVD

Publications by WCN study

Publications WCN studies by WCN member